F18-FDG-PET for recurrent differentiated thyroid cancer: a systematic meta-analysis

BACKGROUND: Positron emission tomography (PET) with fluor-18-deoxy-glucose (FDG) is widely used for diagnosing recurrent or metastatic disease in patients with differentiated thyroid cancer (DTC). PURPOSE: To assess the diagnostic accuracy of FDG-PET for DTC in patients after ablative therapy. MATER...

Descripción completa

Detalles Bibliográficos
Autores principales: Haslerud, Torjan, Brauckhoff, Katrin, Reisæter, Lars, Küfner Lein, Regina, Heinecke, Achim, Varhaug, Jan Erik, Biermann, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2015
Materias:
Head and Neck
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015757/
https://www.ncbi.nlm.nih.gov/pubmed/26163534
http://dx.doi.org/10.1177/0284185115594645
Descripción
Sumario:BACKGROUND: Positron emission tomography (PET) with fluor-18-deoxy-glucose (FDG) is widely used for diagnosing recurrent or metastatic disease in patients with differentiated thyroid cancer (DTC). PURPOSE: To assess the diagnostic accuracy of FDG-PET for DTC in patients after ablative therapy. MATERIAL AND METHODS: A systematic search was conducted in Medline/PubMed, EMBASE, Cochrane Library, Web of Science, and Open Grey looking for all English-language original articles on the performance of FDG-PET in series of at least 20 patients with DTC having undergone ablative therapy including total thyroidectomy. Diagnostic performance measures were pooled using Reitsma’s bivariate model. RESULTS: Thirty-four publications between 1996 and 2014 met the inclusion criteria. Pooled sensitivity and specificity were 79.4% (95% confidence interval [CI], 73.9–84.1) and 79.4% (95% CI, 71.2–85.4), respectively, with an area under the curve of 0.858. CONCLUSION: F18-FDG-PET is a useful method for detecting recurrent DTC in patients having undergone ablative therapy.

Ejemplares similares